Tag Archives: Sharp Therapeutics

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – April 17, 2026) – Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) (“Sharp” or the “Company“) announces the release of its annual audited consolidated financial statements for the year ended December 31, 2025, and related management discussion and analysis (“MD&A“) and annual information form. All dollar …

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – April 2, 2026) – Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) (“Sharp” or the “Company“) is pleased to announce that it has closed the third tranche (the “Third Tranche“) of its previously announced non-brokered private placement for unsecured convertible notes of the Company …

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – May 22, 2025) – Sharp Therapeutics Corp. (TSXV: SHRX) (“Sharp” or the “Company”), a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases, announces the release of its condensed interim consolidated financial statements for the three months ended March 31, 2025, …

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – May 13, 2025) – Sharp Therapeutics Corp. (TSXV: SHRX) (“Sharp” or the “Company”), a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases, announces that it has nominated a small molecule compound from its GBA program for clinical development in Gaucher’s …

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – April 21, 2025) – Sharp Therapeutics Corp. (TSXV: SHRX) (“Sharp” or the “Company”), a pre-clinical-stage biotechnology company developing small molecule therapies to treat hereditary disorders, is pleased to announce that STX PARTNERS LLP (“STX”) and Newlin Investment Company (“NIC”) have each exercised their …